I disagree. The conference call was mentioned in t
Post# of 148172
Also I sent the PR admin assistant an email asking if NP would speak to uplisting updates and if big pharma discussions are still ongoing. To me the latter is the kicker because we know they would have seen the data and are still interested.
If his answer is "we cannot speak about that right now" then that may be a bad sign.
I figured I would send my questions in because last time all the calls were taken up with people giving their life story or trying to get NP to bash the FDA. Wanted some real meat this time. FYI life stories aren't bad but maybe send emails if you are on this message board. Conference calls generally are more business related.
Hope they acknowledge my questions...if not, I'll live.